ANGPTL3 (human) ELISA Kit

Angiopoietin-like protein 3 (ANGPTL3) is a hepatokine belonging to the angiopoietin-like protein family, which shares structural features with angiopoietins but lacks direct involvement in classical vascular receptor signaling. ANGPTL3 is primarily produced in the liver and circulates in plasma as part of a functional complex that also includes ANGPTL8, which enhances its activity in the fed state. Structurally, ANGPTL3 contains an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain; proteolytic cleavage between these domains yields functionally distinct fragments with partially separable biological activities. Beyond its initial description as an angiogenic factor, ANGPTL3 is now recognized as a central regulator of systemic lipid metabolism. Genetic studies in humans and mice have shown that loss-of-function variants in ANGPTL3 are associated with familial combined hypolipidemia and reduced risk of atherosclerotic cardiovascular disease, a phenotype often referred to as “familial combined hypolipidemia.” Conversely, increased ANGPTL3 activity contributes to hypertriglyceridemia and mixed dyslipidemia. Mechanistically, ANGPTL3 inhibits both lipoprotein lipase (LPL) and endothelial lipase (EL), thereby reducing the catabolism of triglyceride-rich lipoproteins and modulating HDL metabolism. Importantly, ANGPTL3 also influences hepatic VLDL production indirectly through interactions with insulin signaling and ANGPTL8, integrating nutritional status with lipid partitioning between tissues. These insights have been reinforced by therapeutic studies showing that ANGPTL3 inhibition lowers plasma triglycerides, LDL cholesterol, and remnant lipoproteins independent of LDL receptor function. Clinically, ANGPTL3 has emerged as a promising therapeutic target for a broad spectrum of dyslipidemias. Monoclonal antibodies (e.g., evinacumab) and antisense oligonucleotides targeting ANGPTL3 have demonstrated significant lipid-lowering effects in patients with refractory hypercholesterolemia, including those with homozygous familial hypercholesterolemia. Collectively, these findings position ANGPTL3 as a key endocrine regulator linking hepatic nutrient sensing to systemic lipid homeostasis and cardiovascular risk. The ANGPTL3 (human) ELISA Kit is to be used for the in vitro quantitative determination of human ANGPTL3 in serum, plasma and cell culture supernatant.